{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/mfds-submissions-and-korean-gcp-alignment”
},
“@id”: “https://www.clinicalstudies.in/mfds-submissions-and-korean-gcp-alignment”,
“headline”: “SOP for MFDS Submissions and Korean GCP Alignment”,
“name”: “SOP for MFDS Submissions and Korean GCP Alignment”,
“description”: “Comprehensive SOP describing sponsor, investigator, and regulatory responsibilities for clinical trial submissions to the Ministry of Food and Drug Safety (MFDS) in South Korea, aligned with Korean GCP.”,
“keywords”: “MFDS submission SOP, Korean GCP alignment SOP, SOP for regulatory submissions South Korea, SOP for CTA South Korea, SOP for clinical trial approvals Korea, SOP for investigator responsibilities MFDS, SOP for sponsor obligations MFDS submissions, SOP for CRO regulatory submissions Korea, SOP for safety reporting MFDS Korea, SOP for regulatory compliance South Korea, SOP for ethics submissions Korea, SOP for trial conduct MFDS compliance, SOP for DSUR submission MFDS, SOP for ICSR reporting Korea, SOP for inspection readiness MFDS, SOP for GCP compliance Korea, SOP for clinical trial dossier submission Korea, SOP for PV reporting Korea, SOP for Korean clinical trial governance, SOP for protocol amendments Korea, SOP for documentation archiving Korea, SOP for sponsor regulatory strategy Korea, SOP for investigator CTA compliance Korea, SOP for RA responsibilities Korea, SOP for QA oversight Korea, SOP for Korean regulatory timelines SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

MFDS Submissions and Korean GCP Alignment SOP

Purpose

The purpose of this SOP is to define processes for submitting clinical trial applications and related documentation to the Ministry of Food and Drug Safety (MFDS) in South Korea, while ensuring full alignment with Korean Good Clinical Practice (KGCP). It ensures that sponsor and investigator obligations are fulfilled in compliance with local regulations and international GCP standards.

Scope

This SOP applies to all clinical trials conducted in South Korea that require MFDS authorization. It covers clinical trial applications (CTA), amendments, safety reporting, DSURs, ICSRs, and archiving. It applies to sponsors, CROs, investigators, regulatory affairs teams, and quality assurance staff engaged in clinical research.

Responsibilities

• Sponsor: Prepares and submits CTA dossier, oversees communications with MFDS, and ensures compliance with KGCP.
• Regulatory Affairs (RA): Compiles required documents, submits applications, and maintains submission logs.
• Principal Investigator (PI): Provides site-level documentation and ensures compliance with approved protocols.
• CRO: Assists with dossier preparation, submissions, and communications with MFDS, as delegated.
• Quality Assurance (QA): Reviews submission packages and ensures inspection readiness.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for timely and complete MFDS submissions. The PI is accountable for site-level compliance with KGCP and MFDS requirements.

Procedure

1. Preparation of CTA Dossier

1. Compile dossier including protocol, Investigator’s Brochure (IB), Informed Consent Form (ICF), Investigator CVs, GMP certificates, and relevant preclinical/CMC data.
2. Ensure translations into Korean where required.
3. Complete Submission Checklist (Annexure-1).

2. Submission to MFDS

1. Submit application electronically to MFDS via official portal.
2. Maintain record of submission reference number in Submission Log (Annexure-2).

3. Ethics Committee (EC) Coordination

1. Submit documents simultaneously to Institutional Review Boards (IRBs) for approval.
2. Ensure IRB approval is aligned with MFDS requirements before trial initiation.

4. Safety Reporting

1. Report SAEs and SUSARs in accordance with MFDS timelines.
2. Submit ICSRs electronically to MFDS pharmacovigilance systems.
3. Prepare annual DSUR and submit within 60 days of data lock point.

5. Amendments

1. Prepare substantial amendment packages including revised protocol, IB, or ICF.
2. Submit to MFDS and IRB for approval prior to implementation.

6. Documentation and Archiving

1. Maintain TMF and ISF per KGCP requirements.
2. Archive documents for a minimum of 10 years post-trial completion.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• CTA: Clinical Trial Application
• PI: Principal Investigator
• RA: Regulatory Affairs
• CRO: Contract Research Organization
• QA: Quality Assurance
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• DSUR: Development Safety Update Report
• ICSR: Individual Case Safety Report
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Submission Checklist (Annexure-1)
2. Submission Log (Annexure-2)
3. Safety Reporting Log (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trials Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: Submission Checklist

Annexure-2: Submission Log

Annexure-3: Safety Reporting Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/esource-and-eclinical-data-expectations”
},
“@id”: “https://www.clinicalstudies.in/esource-and-eclinical-data-expectations”,
“headline”: “SOP for eSource and eClinical Data Expectations”,
“name”: “SOP for eSource and eClinical Data Expectations”,
“description”: “Comprehensive SOP detailing investigator, sponsor, and CRO responsibilities for eSource and eClinical data collection, validation, storage, and submission in South Korea under MFDS regulations.”,
“keywords”: “eSource SOP Korea, eClinical data SOP Korea, SOP for electronic source data Korea, SOP for MFDS eClinical requirements, SOP for electronic CRF Korea, SOP for investigator site electronic data SOP, SOP for sponsor eClinical responsibilities Korea, SOP for CRO electronic data SOP Korea, SOP for data integrity MFDS Korea, SOP for ALCOA principles Korea, SOP for regulatory compliance eSource Korea, SOP for trial master file eClinical Korea, SOP for eClinical inspection readiness Korea, SOP for data validation Korea, SOP for electronic records SOP Korea, SOP for audit trail requirements Korea, SOP for electronic consent data Korea, SOP for clinical trial management systems Korea, SOP for safety database eClinical Korea, SOP for data retention Korea, SOP for eSource to TMF migration Korea, SOP for data authenticity Korea, SOP for electronic records archiving Korea, SOP for secure access electronic data Korea, SOP for GCP compliance eClinical Korea”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

eSource and eClinical Data Expectations SOP

Purpose

This SOP defines processes for managing electronic source (eSource) and eClinical data in clinical trials conducted in South Korea. It ensures compliance with MFDS regulations, Korean Good Clinical Practice (KGCP), and international GCP standards regarding data integrity, authenticity, confidentiality, and retention.

Scope

This SOP applies to all sponsor-led and investigator-initiated trials using eSource, EDC, eCRF, CTMS, or electronic consent systems in South Korea. It covers data entry, validation, security, audit trails, archiving, and regulatory submission of eClinical data.

Responsibilities

• Sponsor: Ensures systems used for eClinical data meet MFDS and KGCP requirements, validates vendor systems, and oversees compliance.
• Principal Investigator (PI): Ensures accurate and timely entry of eSource data, verifies completeness, and protects subject confidentiality.
• Clinical Research Coordinator (CRC): Supports PI in entering and validating eSource data.
• Data Management Team: Maintains database integrity, runs edit checks, and ensures data quality.
• Quality Assurance (QA): Audits systems for compliance with ALCOA principles and data integrity.
• CRO: Provides system support and ensures delegated tasks meet MFDS compliance standards.

Accountability

The Sponsor’s Head of Data Management is accountable for compliance with MFDS eClinical requirements. The PI is accountable for ensuring subject data accuracy and integrity at site level.

Procedure

1. System Validation

1. Ensure all eClinical systems are validated per 21 CFR Part 11 and MFDS requirements.
2. Maintain System Validation Report in TMF (Annexure-1).

2. Data Entry and Validation

1. Record eSource data directly into validated systems (EDC, eCRF).
2. Perform edit checks and query resolution to ensure accuracy.
3. PI must verify final data entries with electronic signature.

3. Audit Trail

1. Ensure all changes to data are recorded with user ID, date, time, and reason.
2. Audit trails must be reviewable and retained with study records.

4. Data Security

1. Grant access only to authorized personnel.
2. Implement role-based permissions and password controls.
3. Back up eClinical data daily and store securely.

5. Data Submission to MFDS

1. Prepare eClinical datasets per MFDS formatting requirements.
2. Submit datasets and associated metadata for regulatory review.

6. Archiving

1. Archive eClinical data, metadata, and audit trails in TMF and ISF.
2. Ensure minimum retention of 10 years post-study, or longer if required by MFDS.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• eSource: Electronic Source Data
• EDC: Electronic Data Capture
• eCRF: Electronic Case Report Form
• CTMS: Clinical Trial Management System
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• QA: Quality Assurance
• CRO: Contract Research Organization
• ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. System Validation Report (Annexure-1)
2. Submission Log (Annexure-2)
3. Audit Trail Report (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• FDA 21 CFR Part 11 Guidance

Version: 1.0

Approval

Annexures

Annexure-1: System Validation Report

Annexure-2: Submission Log

Annexure-3: Audit Trail Report

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/korean-language-consent-and-document-localization”
},
“@id”: “https://www.clinicalstudies.in/korean-language-consent-and-document-localization”,
“headline”: “SOP for Korean Language Consent and Document Localization”,
“name”: “SOP for Korean Language Consent and Document Localization”,
“description”: “Comprehensive SOP describing sponsor and investigator responsibilities for preparing Korean-language informed consent forms and ensuring accurate localization of essential trial documents in compliance with MFDS and Korean GCP.”,
“keywords”: “Korean consent SOP, SOP for document localization Korea, SOP for clinical trial translations Korea, SOP for informed consent Korean language, SOP for essential documents Korea, SOP for ICF Korean translation SOP, SOP for subject-facing documents Korea, SOP for translation vendor SOP Korea, SOP for patient safety documents Korea, SOP for ethics submissions Korea, SOP for BASEC equivalent Korea, SOP for Korean trial governance, SOP for investigator responsibilities Korean documentation, SOP for sponsor translation oversight Korea, SOP for regulatory submissions Korea, SOP for eConsent Korean requirements, SOP for cultural adaptation of trial materials Korea, SOP for patient comprehension SOP Korea, SOP for bilingual documentation Korea, SOP for audit readiness translation Korea, SOP for archiving translated records Korea, SOP for data integrity in translations Korea, SOP for GCP compliance Korean documentation, SOP for CRO translation responsibilities Korea, SOP for inspection readiness Korean trials”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Korean Language Consent and Document Localization SOP

Purpose

This SOP defines requirements for preparing informed consent forms (ICFs) and essential documents in the Korean language, ensuring cultural, linguistic, and regulatory compliance. It ensures participant comprehension, ethical compliance, and alignment with MFDS and Korean GCP standards.

Scope

This SOP applies to all clinical trials conducted in South Korea where subject-facing documents and essential regulatory documents require Korean language localization. It covers translation, back-translation, certification, cultural adaptation, ethics submissions, and archiving of localized records.

Responsibilities

• Sponsor: Ensures availability of ICFs and subject-facing materials in Korean, oversees translation processes, and verifies certification.
• Principal Investigator (PI): Ensures participants understand the content of the ICF and maintains localized versions in the ISF.
• Regulatory Affairs (RA): Submits localized documents to MFDS and ethics committees.
• Translation Vendor: Provides certified translations and back-translations of documents.
• Quality Assurance (QA): Audits translation and localization processes to ensure compliance with KGCP.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring localized document availability. The PI is accountable for confirming comprehension during the consent process.

Procedure

1. Identification of Documents Requiring Localization

1. Prepare a list of documents needing translation (ICFs, PIS, subject leaflets, safety reports).
2. Document requirements in Translation Tracker (Annexure-1).

2. Translation and Back-Translation

1. Engage certified medical translators for Korean translation.
2. Perform back-translation into English to verify accuracy.
3. Retain Certificate of Translation Accuracy in TMF.

3. Ethics Submission

1. Submit localized ICFs and patient materials to ethics committees and MFDS.
2. Maintain acknowledgment letters in Submission Log (Annexure-2).

4. Consent Process

1. Ensure that PIs or delegated staff explain the consent form to participants in Korean.
2. Confirm comprehension by asking subjects to summarize key points.

5. Archiving

1. Maintain localized documents in ISF and TMF for at least 10 years post-study.
2. Ensure availability for inspections and audits.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• ICF: Informed Consent Form
• PIS: Patient Information Sheet
• ISF: Investigator Site File
• TMF: Trial Master File
• RA: Regulatory Affairs
• QA: Quality Assurance
• PI: Principal Investigator

Documents

1. Translation Tracker (Annexure-1)
2. Submission Log (Annexure-2)
3. Certificate of Translation Accuracy (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trials Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: Translation Tracker

Annexure-2: Submission Log

Annexure-3: Certificate of Translation Accuracy

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/local-pv-reporting-and-audits”
},
“@id”: “https://www.clinicalstudies.in/local-pv-reporting-and-audits”,
“headline”: “SOP for Local PV Reporting and Audits”,
“name”: “SOP for Local PV Reporting and Audits”,
“description”: “Comprehensive SOP describing sponsor, investigator, and CRO responsibilities for local pharmacovigilance (PV) reporting and audits in South Korea, in compliance with MFDS and KGCP requirements.”,
“keywords”: “MFDS safety reporting SOP, local PV reporting Korea, ICSR submission Korea, SOP for pharmacovigilance Korea, SOP for SUSAR reporting MFDS, SOP for SAE reporting Korea, SOP for expedited safety reporting Korea, SOP for DSUR submission Korea, SOP for PV database Korea, SOP for safety reporting timelines Korea, SOP for QPPV Korea, SOP for investigator safety reporting Korea, SOP for sponsor PV obligations Korea, SOP for CRO pharmacovigilance Korea, SOP for inspection readiness PV Korea, SOP for pharmacovigilance compliance Korea, SOP for regulatory safety reporting Korea, SOP for adverse reaction reporting Korea, SOP for safety case documentation Korea, SOP for GCP compliance PV Korea, SOP for trial subject safety Korea, SOP for audit readiness safety Korea, SOP for local PV governance Korea, SOP for MFDS pharmacovigilance compliance, SOP for safety reporting and audits Korea”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Local PV Reporting and Audits SOP

Purpose

The purpose of this SOP is to establish a standardized process for local pharmacovigilance (PV) reporting and audits in South Korea. It ensures compliance with Ministry of Food and Drug Safety (MFDS) regulations, Korean Good Clinical Practice (KGCP), and international safety reporting standards, thereby safeguarding trial participants and ensuring data integrity.

Scope

This SOP applies to all clinical trials conducted in South Korea under sponsor or investigator responsibility. It includes SAE, SUSAR, and ICSR reporting to MFDS, submission of Development Safety Update Reports (DSURs), PV system audits, and archiving of safety documentation. It applies to sponsors, CROs, investigators, PV officers, and regulatory affairs staff.

Responsibilities

• Sponsor PV Team: Collects, evaluates, and reports safety cases to MFDS and ensures timelines are met.
• Principal Investigator (PI): Reports SAEs to sponsor within 24 hours and files SAE forms in ISF.
• Clinical Research Coordinator (CRC): Supports PI in SAE documentation and maintains site safety records.
• Regulatory Affairs (RA): Submits safety reports, DSURs, and ensures acknowledgment from MFDS.
• Quality Assurance (QA): Conducts audits of PV systems to verify compliance with MFDS and KGCP.
• CRO (if applicable): Supports sponsor in PV reporting and audit preparation.

Accountability

The sponsor’s Qualified Person for Pharmacovigilance (QPPV) or designated local safety officer in South Korea is accountable for PV compliance and audit readiness. The PI is accountable for site-level reporting and documentation.

Procedure

1. SAE and SUSAR Reporting

1. Investigators must notify sponsor of SAEs within 24 hours using SAE forms.
2. Sponsor PV team assesses seriousness, expectedness, and causality of events.
3. SUSARs must be reported to MFDS within 7 days (fatal/life-threatening) or 15 days (others).

2. ICSR Submissions

1. Prepare ICSRs using MFDS reporting format and electronic submission system.
2. Log submissions in ICSR Tracker (Annexure-1).

3. DSUR Preparation and Submission

1. Prepare DSUR annually with cumulative safety data.
2. Submit DSUR to MFDS within 60 days of data lock point.

4. PV Audits

1. QA team conducts annual audits of PV systems, safety case processing, and reporting timelines.
2. Document audit findings and CAPA in Audit Log (Annexure-2).

5. Documentation and Archiving

1. Maintain SAE logs, SUSAR logs, ICSR submissions, DSURs, and audit reports in TMF and ISF.
2. Archive PV documentation for at least 10 years in compliance with MFDS.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• PV: Pharmacovigilance
• QPPV: Qualified Person for Pharmacovigilance
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• ICSR: Individual Case Safety Report
• DSUR: Development Safety Update Report
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• RA: Regulatory Affairs
• QA: Quality Assurance
• ISF: Investigator Site File
• TMF: Trial Master File

Documents

1. ICSR Tracker (Annexure-1)
2. Audit Log (Annexure-2)
3. DSUR Submission Log (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• ICH E2F: Development Safety Update Report

Version: 1.0

Approval

Annexures

Annexure-1: ICSR Tracker

Annexure-2: Audit Log

Annexure-3: DSUR Submission Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/local-pv-reporting-and-audits-korea”
},
“@id”: “https://www.clinicalstudies.in/local-pv-reporting-and-audits-korea”,
“headline”: “SOP for Local PV Reporting and Audits”,
“name”: “SOP for Local PV Reporting and Audits”,
“description”: “Detailed SOP describing sponsor, investigator, and CRO responsibilities for local pharmacovigilance reporting and audits in South Korea under MFDS regulations and KGCP.”,
“keywords”: “Korean PV reporting SOP, SOP for pharmacovigilance Korea, SOP for safety case management Korea, SOP for ICSR reporting Korea, SOP for DSUR submission Korea, SOP for SUSAR reporting Korea, SOP for SAE reporting Korea, SOP for expedited safety submissions Korea, SOP for safety database Korea, SOP for local regulatory reporting Korea, SOP for investigator safety responsibilities Korea, SOP for sponsor PV obligations Korea, SOP for CRO PV activities Korea, SOP for pharmacovigilance audits Korea, SOP for GCP compliance Korea, SOP for MFDS safety governance, SOP for adverse reaction reporting Korea, SOP for PV inspection readiness Korea, SOP for safety record keeping Korea, SOP for trial subject safety Korea, SOP for audit trail pharmacovigilance Korea, SOP for MFDS safety timelines Korea, SOP for electronic PV submissions Korea, SOP for regulatory compliance Korea, SOP for safety reporting documentation Korea”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Local PV Reporting and Audits SOP

Purpose

This SOP establishes standardized procedures for local pharmacovigilance (PV) reporting and audits in South Korea. It ensures compliance with MFDS safety reporting timelines, Korean GCP (KGCP), and international guidelines, thereby protecting patient safety and ensuring inspection readiness.

Scope

This SOP applies to all clinical trials conducted in South Korea under sponsor or investigator responsibility. It includes safety case collection, SAE/SUSAR reporting, ICSR submission, DSUR preparation, PV audits, and archiving of safety documents. It applies to sponsors, CROs, investigators, PV officers, QA, and regulatory affairs staff.

Responsibilities

• Sponsor PV Team: Oversees safety case management, prepares ICSR and DSUR reports, and ensures submission to MFDS within timelines.
• Principal Investigator (PI): Identifies, documents, and reports SAEs within 24 hours to sponsor.
• CRC: Supports PI in documentation and reporting of adverse events.
• Regulatory Affairs (RA): Submits safety reports and ensures acknowledgment from MFDS.
• Quality Assurance (QA): Conducts audits on PV processes, documentation, and timelines.
• CRO (if delegated): Provides PV reporting support and ensures alignment with MFDS requirements.

Accountability

The sponsor’s Qualified Person for Pharmacovigilance (QPPV) or designated Korean safety officer is accountable for PV compliance. The PI is accountable for ensuring site-level safety reporting.

Procedure

1. SAE and SUSAR Reporting

1. Document SAEs in SAE forms and notify sponsor within 24 hours.
2. Sponsor PV team evaluates seriousness, causality, and expectedness.
3. Fatal or life-threatening SUSARs: submit within 7 days; all others within 15 days.

2. ICSR Submissions

1. Prepare ICSRs in MFDS-compliant electronic format.
2. Submit through MFDS PV reporting systems.
3. Log cases in ICSR Log (Annexure-1).

3. DSUR Preparation and Submission

1. Compile DSUR annually with cumulative global and local safety data.
2. Submit DSUR to MFDS within 60 days of data lock point.

4. PV Audits

1. QA team performs annual audits of PV systems and safety databases.
2. Audit findings are documented with CAPA in Audit Log (Annexure-2).

5. Documentation and Archiving

1. Maintain SAE forms, SUSAR reports, ICSR logs, DSURs, and audit reports in TMF/ISF.
2. Archive PV records for a minimum of 10 years as per MFDS requirements.

Abbreviations

• MFDS: Ministry of Food and Drug Safety
• KGCP: Korean Good Clinical Practice
• PV: Pharmacovigilance
• QPPV: Qualified Person for Pharmacovigilance
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• ICSR: Individual Case Safety Report
• DSUR: Development Safety Update Report
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• RA: Regulatory Affairs
• QA: Quality Assurance
• ISF: Investigator Site File
• TMF: Trial Master File

Documents

1. ICSR Log (Annexure-1)
2. Audit Log (Annexure-2)
3. DSUR Submission Log (Annexure-3)

References

• MFDS — Ministry of Food and Drug Safety
• ICH E6(R2) Good Clinical Practice
• ICH E2F: Development Safety Update Report

Version: 1.0

Approval

Annexures

Annexure-1: ICSR Log

Annexure-2: Audit Log

Annexure-3: DSUR Submission Log

Revision History

For more SOPs visit: Pharma SOP.